Drug Profile
MV 9411
Alternative Names: MV9411Latest Information Update: 29 Mar 2011
Price :
$50
*
At a glance
- Originator Miravant Medical Technologies
- Class Skin disorder therapies
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 07 Feb 2002 Phase-II clinical trials for Psoriasis in USA (Topical)
- 09 Nov 2001 A phase I trial in volunteers has been completed
- 22 Jun 2001 Phase-I clinical trials for Psoriasis in USA (Topical)